Rgenix Stock

Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating first-in-class therapeutics that target key nodes in cancer progression. Its proprietary discovery platform is based on innovations in cancer biology that enable the identification and validation of novel post-transcriptionally regulated targets. Rgenix’s productive approach has yielded multiple novel targets to date across several cancer types for which the company is developing drugs, and its scientific approach has led to the discovery of novel therapeutic targets and first-in-class drugs for several cancer sub-types, including melanoma, colorectal cancer and triple-negative breast cancer, among others. Its aim is to discover and develop safe, effective, and commercially viable therapies that will transform the lives of cancer patients by treating metastatic disease. Rgenix was developed by founding scientists Dr. Sohail Tavazoie and Dr. Saeed Tavazoie. It was launched in 2010.